Evidence map›Paper›PMID 37060527›Full record

ArticlePharmacological reports : PR2023

Effects of chronic delta-opioid receptor agonist on the excitability of hippocampal glutamate and brainstem monoamine neurons, anxiety, locomotion, and habituation in rats.

Eliyahu Dremencov, Daniil Grinchii, Zuzana Romanova, Pavol Chomanic, Lubica Lacinova, Daniela Jezova

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmacological reports : PR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Eliyahu DremencovInstitute of Molecular Physiology and Genetics, Center of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, Bratislava, Slovakia. eliyahu.dremencov@savba.sk.ORCID http://orcid.org/0000-0001-8103-8577
Daniil GrinchiiInstitute of Molecular Physiology and Genetics, Center of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, Bratislava, Slovakia.
Zuzana RomanovaInstitute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
Pavol ChomanicInstitute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
Lubica LacinovaInstitute of Molecular Physiology and Genetics, Center of Biosciences, Slovak Academy of Sciences, Dúbravská cesta 9, Bratislava, Slovakia.
Daniela JezovaInstitute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
Slovak Academy of Sciences · SKInstitute of Chemistry of the Slovak Academy of Sciences · SK

Funding

Agentúra na Podporu Výskumu a Vývoja APVV-18-0283Agentúra na Podporu Výskumu a Vývoja APVV-19-0435Deutsches Zentrum für Luft- und Raumfahrt Era Net UNMET project (NEURON-051)Vedecká Grantová Agentúra MŠVVaŠ SR a SAV 2/0057/22
6 · The paper itself

Abstract

backgroundShort-term treatment with non-peptide agonists of delta-opioid receptors, such as agonist SNC80, induced behavioral effects in rodents, which could be modulated via changes in central neurotransmission. The present experiments aimed at testing the hypothesis that chronic treatment with SNC80 induces anxiolytic effects associated with changes in hippocampal glutamate and brainstem monoamine pathways.

methodsAdult male Wistar rats were used in experiments. Rats were treated with SNC80 (3 mg/kg/day) for fourteen days. Neuronal excitability was assessed using extracellular in vivo single-unit electrophysiology. The behavioral parameters were examined using the elevated plus maze and open field tests.

resultsChronic SNC80 treatment increased the excitability of hippocampal glutamate and ventral tegmental area dopamine neurons and had no effect on the firing activity of dorsal raphe nucleus serotonin cells. Chronic SNC80 treatment induced anxiolytic effects, which were, however, confounded by increased locomotor activity clearly confirmed in an open field test. The ability to cope with stressful situations and habituation processes in a novel environment was not influenced by chronic treatment with SNC80.

conclusionOur study suggests that the psychoactive effects of SNC80 might be explained by its ability to stimulate hippocampal glutamate and mesolimbic dopamine transmission.

Indexed as

Anti-Anxiety AgentsGlutamic AcidAnalgesics, OpioidAnimalsAnxietyBenzamidesBrain StemHabituation, PsychophysiologicHippocampusLocomotionMaleNeuronsPiperazinesRatsRats, WistarReceptors, Opioid4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamideAnalgesics, OpioidAnti-Anxiety AgentsBenzamidesGlutamic AcidPiperazinesReceptors, OpioidBehaviorDelta-opioid receptor (DOR)Dorsal raphe nucleus (DRN)ElectrophysiologyHippocampusVentral tegmental area (VTA)

Identifiers

PMID37060527
OpenAlexW4365810917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.